This highly interdisciplinary project aims to develop an optimal nano-in-nano vector for cancer targeted theranostics. The proposed nanovector merges the favorable features of calcium phosphate nanoparticles, such as biocompatibility, biodegradability and pH-responsive release of payloads, those of drug nanocrystals including the ultrahigh drug loading degree and enhanced dissolution rate, and contrast agent nanoparticles for non-invasive imaging of tumor malignancy. Overall, this theranostic nanovector is expected to simultaneously boost contrast agents relaxivity when the contrast agent is discharged from the disintegrative calcium phosphate shell, and to kill the cancer cells when ultrahigh mass fraction of therapeutics is released, in response to the intratumoral pH.
|Todellinen alku/loppupvm||01/09/2017 → 31/08/2020|
- SUOMEN AKATEMIA: 279 990,00 €
- 317 Farmasia
- 216 Materiaalitekniikka